[8-K] Gain Therapeutics, Inc. Reports Material Event
Gain Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Current Report. The filing also references an Interactive Data File as Exhibit 104.
The registrant indicates it is an emerging growth company and its common stock trades under GANX on The NASDAQ Stock Market. The company states the press release and related information are furnished and therefore are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except by specific reference. This 8-K does not include the financial statements or numeric results within its text.
Gain Therapeutics, Inc. ha pubblicato un comunicato stampa con i risultati finanziari per il trimestre terminato 30 giugno 2025 e ha fornito un aggiornamento sull'attività; tale comunicato è allegato come Exhibit 99.1 al presente Current Report. Il deposito fa inoltre riferimento a un Interactive Data File come Exhibit 104.
La società dichiara di essere un emerging growth company e che le sue azioni ordinarie sono negoziate con il simbolo GANX sul Nasdaq. La società afferma che il comunicato stampa e le informazioni correlate sono furnished e pertanto non sono considerate filed ai fini della Sezione 18 dell'Exchange Act e non sono incorporate per riferimento in altri depositi salvo che con specifico riferimento. Questo Form 8-K non include i bilanci o risultati numerici nel testo.
Gain Therapeutics, Inc. publicó un comunicado de prensa con los resultados financieros del trimestre terminado el 30 de junio de 2025 y proporcionó una actualización comercial; dicho comunicado se adjunta como Exhibit 99.1 en este Current Report. El expediente también hace referencia a un Interactive Data File como Exhibit 104.
La registrante indica que es una emerging growth company y que sus acciones ordinarias cotizan bajo GANX en el Nasdaq. La compañía declara que el comunicado y la información relacionada se han furnished y, por lo tanto, no se consideran filed a los efectos de la Sección 18 del Exchange Act y no se incorporan por referencia en otros documentos salvo que se indique expresamente. Este Form 8-K no incluye estados financieros ni resultados numéricos en su texto.
Gain Therapeutics, Inc.은 2025년 6월 30일로 끝나는 분기의 재무 실적을 발표하는 보도자료를 제공하고 경영 현황을 업데이트했습니다. 해당 보도자료는 본 Current Report의 Exhibit 99.1로 첨부되어 있습니다. 제출서류는 또한 Interactive Data File을 Exhibit 104로 참조하고 있습니다.
보고기업은 emerging growth company임을 밝히고, 보통주는 NASDAQ에서 GANX로 거래된다고 기재했습니다. 회사는 보도자료 및 관련 정보가 furnished된 것으로서 filed된 것으로 간주되지 않으며 Exchange Act의 Section 18 목적상 제출된 것으로 인정되지 않고, 별도의 명시적 언급이 있는 경우를 제외하고 다른 제출서류에 의해 참고로 포함되지 않는다고 명시했습니다. 이 Form 8-K에는 본문 내에 재무제표나 수치 결과가 포함되어 있지 않습니다.
Gain Therapeutics, Inc. a publié un communiqué de presse annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025 et a fourni une mise à jour sur ses activités ; ce communiqué est inclus en tant que Exhibit 99.1 dans ce Current Report. Le dépôt fait également référence à un Interactive Data File en tant que Exhibit 104.
La société déclarante indique être une emerging growth company et que ses actions ordinaires se négocient sous le symbole GANX sur le NASDAQ. La société précise que le communiqué et les informations connexes sont furnished et, par conséquent, ne sont pas réputés filed aux fins de la Section 18 de l'Exchange Act et ne sont pas incorporés par référence dans d'autres dépôts sauf mention expresse. Ce Form 8-K n'inclut pas les états financiers ni les résultats chiffrés dans son texte.
Gain Therapeutics, Inc. veröffentlichte eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 und gab ein Geschäftsupdate; diese Pressemitteilung ist als Exhibit 99.1 in diesem Current Report enthalten. Die Einreichung verweist außerdem auf eine Interactive Data File als Exhibit 104.
Der Registrant gibt an, ein emerging growth company zu sein, und seine Stammaktien werden unter GANX an der NASDAQ gehandelt. Das Unternehmen erklärt, dass die Pressemitteilung und die zugehörigen Informationen furnished wurden und daher nicht als filed im Sinne der Section 18 des Exchange Act gelten und nicht durch Verweisung in andere Einreichungen aufgenommen werden, es sei denn durch ausdrückliche Bezugnahme. Dieses Form 8-K enthält keine Finanzabschlüsse oder numerischen Ergebnisse im Text.
- None.
- None.
Insights
TL;DR: Routine earnings press release furnished to the SEC; no financial figures in the 8-K itself limits immediate investor assessment.
The filing notifies investors that a press release with second-quarter results and a business update was furnished as Exhibit 99.1, which signals timely disclosure of corporate results. Because the release is furnished and not filed under Section 18, the 8-K explicitly limits legal incorporation into other filings. Without numeric results or metrics included in this document, users must consult the furnished press release to evaluate performance or revisions to guidance.
TL;DR: Procedural 8-K confirming disclosure of Q2 results and business update; governance implications are routine and non-material on the face of the filing.
The document follows standard disclosure practice by furnishing the press release and identifying exhibits, and it confirms the company’s emerging growth company status. The specific statement that the exhibit is furnished and not deemed filed is a common legal carve-out to limit Section 18 liability. There are no governance changes, officer departures, or material agreements disclosed in this filing.
Gain Therapeutics, Inc. ha pubblicato un comunicato stampa con i risultati finanziari per il trimestre terminato 30 giugno 2025 e ha fornito un aggiornamento sull'attività; tale comunicato è allegato come Exhibit 99.1 al presente Current Report. Il deposito fa inoltre riferimento a un Interactive Data File come Exhibit 104.
La società dichiara di essere un emerging growth company e che le sue azioni ordinarie sono negoziate con il simbolo GANX sul Nasdaq. La società afferma che il comunicato stampa e le informazioni correlate sono furnished e pertanto non sono considerate filed ai fini della Sezione 18 dell'Exchange Act e non sono incorporate per riferimento in altri depositi salvo che con specifico riferimento. Questo Form 8-K non include i bilanci o risultati numerici nel testo.
Gain Therapeutics, Inc. publicó un comunicado de prensa con los resultados financieros del trimestre terminado el 30 de junio de 2025 y proporcionó una actualización comercial; dicho comunicado se adjunta como Exhibit 99.1 en este Current Report. El expediente también hace referencia a un Interactive Data File como Exhibit 104.
La registrante indica que es una emerging growth company y que sus acciones ordinarias cotizan bajo GANX en el Nasdaq. La compañía declara que el comunicado y la información relacionada se han furnished y, por lo tanto, no se consideran filed a los efectos de la Sección 18 del Exchange Act y no se incorporan por referencia en otros documentos salvo que se indique expresamente. Este Form 8-K no incluye estados financieros ni resultados numéricos en su texto.
Gain Therapeutics, Inc.은 2025년 6월 30일로 끝나는 분기의 재무 실적을 발표하는 보도자료를 제공하고 경영 현황을 업데이트했습니다. 해당 보도자료는 본 Current Report의 Exhibit 99.1로 첨부되어 있습니다. 제출서류는 또한 Interactive Data File을 Exhibit 104로 참조하고 있습니다.
보고기업은 emerging growth company임을 밝히고, 보통주는 NASDAQ에서 GANX로 거래된다고 기재했습니다. 회사는 보도자료 및 관련 정보가 furnished된 것으로서 filed된 것으로 간주되지 않으며 Exchange Act의 Section 18 목적상 제출된 것으로 인정되지 않고, 별도의 명시적 언급이 있는 경우를 제외하고 다른 제출서류에 의해 참고로 포함되지 않는다고 명시했습니다. 이 Form 8-K에는 본문 내에 재무제표나 수치 결과가 포함되어 있지 않습니다.
Gain Therapeutics, Inc. a publié un communiqué de presse annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025 et a fourni une mise à jour sur ses activités ; ce communiqué est inclus en tant que Exhibit 99.1 dans ce Current Report. Le dépôt fait également référence à un Interactive Data File en tant que Exhibit 104.
La société déclarante indique être une emerging growth company et que ses actions ordinaires se négocient sous le symbole GANX sur le NASDAQ. La société précise que le communiqué et les informations connexes sont furnished et, par conséquent, ne sont pas réputés filed aux fins de la Section 18 de l'Exchange Act et ne sont pas incorporés par référence dans d'autres dépôts sauf mention expresse. Ce Form 8-K n'inclut pas les états financiers ni les résultats chiffrés dans son texte.
Gain Therapeutics, Inc. veröffentlichte eine Pressemitteilung mit den Finanzergebnissen für das Quartal zum 30. Juni 2025 und gab ein Geschäftsupdate; diese Pressemitteilung ist als Exhibit 99.1 in diesem Current Report enthalten. Die Einreichung verweist außerdem auf eine Interactive Data File als Exhibit 104.
Der Registrant gibt an, ein emerging growth company zu sein, und seine Stammaktien werden unter GANX an der NASDAQ gehandelt. Das Unternehmen erklärt, dass die Pressemitteilung und die zugehörigen Informationen furnished wurden und daher nicht als filed im Sinne der Section 18 des Exchange Act gelten und nicht durch Verweisung in andere Einreichungen aufgenommen werden, es sei denn durch ausdrückliche Bezugnahme. Dieses Form 8-K enthält keine Finanzabschlüsse oder numerischen Ergebnisse im Text.
FAQ
What did Gain Therapeutics (GANX) report in this 8-K?
Is the press release in the 8-K considered filed with the SEC?
Does this 8-K include the company’s financial statements or numeric results?
What exhibits are listed in the filing?
Is Gain Therapeutics an emerging growth company and where is its stock traded?
